Inflammation and cardiovascular diseases: Lessons that can be learned for the patient with cardiogenic shock in the intensive care unit

Current Opinion in Critical Care

Volumn 10, Issue 5, 2004, Pages 347-353

  Geppert, Alexander ^a   Huber, Kurt ^a  

^a Cardiovascular Intensive Care Unit   (Austria)

Author keywords

Antiinflammation; Cardiogenic shock; Glycoprotein IIb IIIa antagonist; Inflammation; Interleukin; Nitric oxide synthase inhibitor; Statins

Indexed keywords

ABCIXIMAB; N(G) METHYLARGININE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PEXELIZUMAB; STATINE DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ATHEROSCLEROSIS; CARDIOGENIC SHOCK; CARDIOVASCULAR DISEASE; CORONARY STENT; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; IMMUNOMODULATION; INFLAMMATION; INTENSIVE CARE; MORTALITY; OUTCOMES RESEARCH; PATHOGENESIS; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY; REVIEW; THROMBOSIS;

ANTIBODIES, MONOCLONAL; CARDIOVASCULAR DISEASES; ENZYME INHIBITORS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFLAMMATION; INTENSIVE CARE UNITS; SHOCK, CARDIOGENIC;

EID: 4744351472     PISSN: 10705295     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ccx.0000139364.53198.fd     Document Type: Review

References (71)

1. Liuzzo G, Biasucci LM, Gallimore JR, et al.: The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 1994, 331:417-424.
2. Toss H, Lindahl B, Siegbahn A, et al.: Prognostic influence of increased fibrinogen and C-reactive protein levels in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. Circulation 1997, 96:4204-4210.
3. Lindahl B, Toss H, Siegbahn A, et al.: Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during instability in coronary artery disease. N Engl J Med 2000, 343:1139-1147.
4. Blankenberg S, Rupprecht HJ, Bickel C, et al.: Circulating cell adhesion molecules and death in patients with coronary artery disease. Circulation 2001, 104:1336-1342.
5. Biasucci LM, Liuzzo G, Fantuzzi G, et al.: Increasing levels of interleukin (IL)-1 Ra and IL-6 during the first 2 days of hospitalization in unstable angina are associated with increased risk of in-hospital coronary events. Circulation 1999, 99:2079-2084.
6. Dibra A, Mehilli J, Braun S, et al.: Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003, 114:715-722.
7. Mueller C, Buettner HJ, Hodgson JM, et al.: Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002, 105:1412-1415.
8. Walter DH, Fichtlscherer S, Sellwig M, et al.: Preprocedural C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001, 37:839-846.
9. de Winter RJ, Heyde GS, Koch KT, et al.: The prognostic value of pre-procedural plasma C-reactive protein in patients undergoing elective coronary angioplasty. Eur Heart J 2002, 23:960-966.
10. Kukielka GL, Smith CW, Manning AM, et al.: Induction of interleukin-6 synthesis in the myocardium: potential role in postreperfusion inflammatory injury. Circulation 1995, 92:1866-1875.
11. Neumann FJ, Ott I, Gawaz M, et al.: Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. Circulation 1995, 92:748-755.
12. Cusack MR, Marber MS, Lambiase PD, et al.: Systemic inflammation in unstable angina is the result of myocardial necrosis. J Am Coll Cardiol 2002, 39:1917-1923.
13. Benamer H, Steg PG, Benessiano J, et al.: Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris. Am J Cardiol 1998, 82:845-850.
14. Rebuzzi AG, Quaranta G, Liuzzo G, et al.: Incremental prognostic value of serum levels of troponin T and C-reactive protein on admission in patients with unstable angina pectoris. Am J Cardiol 1998, 82:715-719.
15. Chew DP, Bhatt DL, Robbins MA, et al.: Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention. Circulation 2001, 104:992-997.
16. Morrow DA, Rifai N, Antman EM, et al.: C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy: thrombolysis in myocardial infarction. J Am Coll Cardiol 1998, 31:1460-1465.
17. Pearson TA, Mensah GA, Alexander RW, et al.: Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107:499-511. This article, as a statement for daily practice, summarizes the current understanding of inflammation and coronary artery diseases and outlines which tests should be performed, in which patients, and in which clinical settings.
18. Sheiban I, Moretti C, Oliaro E, et al.: Evolving standard in the treatment of coronary artery disease: drug-eluting stents. Minerva Cardioangiol 2003, 51:485-492.
19. Stone GW, Ellis SG, Cox DA, et al.: One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation 2004, 109:1942-1947.
20. Morice MC, Serruys PW, Sousa JE, et al: A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002, 346:1773-1780.
21. Mortensen RF: C-reactive protein, inflammation, and innate immunity. Immunol Res 2001, 24:163-176.
22. Cermak J, Key NS, Bach RR, et al.: C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor. Blood 1993, 82:513-520.
23. Fichtlscherer S, Rosenberger G, Walter DH, et al.: Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000, 102:1000-1006.
24. Pasceri V, Willerson JT, Yeh ET: Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000, 102:2165-2168.
25. Libby P, Ridker PM, Maseri A: Inflammation and atherosclerosis. Circulation 2002, 105:1135-1143.
26. Blake GJ, Ridker PM: C-reactive protein and other inflammatory risk markers in acute coronary syndromes. J Am Coll Cardiol 2003, 41:37S-42S. This review summarizes the current knowledge of the relation between inflammatory markers and acute coronary syndromes, discussing not only CRP but also many other inflammatory markers.
27. Rosenson RS, Koenig W: Utility of inflammatory markers in the management of coronary artery disease. Am J Cardiol 2003, 92:10i-18i. This review summarizes recent findings in the field and focuses on the modulation of the inflammatory system by cardiovascular drugs.
28. Lindmark E, Diderholm E, Wallentin L, et al.: Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA 2001, 286:2107-2113.
29. Warren BL, Eid A, Singer P, et al.: Caring for the critically ill patient: high-dose antithrombin III in severe sepsis: a randomized controlled trial. JAMA 2001, 286:1869-1878.
30. Bernard GR, Vincent JL, Laterre PF, et al.: Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001, 344:699-709.
31. Ridker PM, Cushman M, Stampfer MJ, et al.: Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
32. Ikonomidis I, Andreotti F, Economou E, et al.: Increased proinflammatory cytokines in patients with chronic stable angina and their reduction by aspirin. Circulation 1999, 100:793-798.
33. Chew DP, Bhatt DL, Robbins MA, et al.: Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol 2001, 88:672-674.
34. Albert MA, Danielson E, Rifai N, et al.: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
35. Kinlay S, Timms T, Clark M, et al.: Comparison of effect of intensive lipid lowering with atorvastatin to less intensive lowering with lovastatin on C-reactive protein in patients with stable angina pectoris and inducible myocardial ischemia. Am J Cardiol 2002, 89:1205-1207.
36. Ridker PM, Rifai N, Pfeffer MA, et al.: Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels: Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998, 98:839-844.
37. Ridker PM, Rifai N, Clearfield M, et al.: Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001, 344:1959-1965.
38. Ridker PM, Rifai N, Lowenthal SP: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001, 103:1191-1193.
39. Ridker PM: Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation 2003, 108:2292-2297.
40. Rosenson RS, Bays HE: Results of two clinical trials on the safety and efficacy of pravastatin 80 and 160 mg per day. Am J Cardiol 2003, 91:878-881.
41. Plenge JK, ernandez TL, Weil KM, et al.: Simvastatin lowers C-reactive protein within 14 days: an effect independent of low-density lipoprotein cholesterol reduction. Circulation 2002, 106:1447-1452.
42. Heeschen C, Hamm CW, Laufs U, et al.: Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002, 105:1446-1452.
43. Gaspardone A, Versaci F, Proietti I, et al.: Effect of atorvastatin (80 mg) initiated at the time of coronary artery stent implantation on C-reactive protein and six-month clinical events. Am J Cardiol 2002, 90:786-789.
44. Cannon CP, Braunwald E, McCabe CH, et al.: Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504. This study shows that among patients who have recently had an acute coronary syndrome, an intensive lipid-lowering statin regimen provides greater protection against death or major cardiovascular events than does a standard regimen.
45. Correia LC, Sposito AC, Lima JC, et al.: Anti-inflammatory effect of atorvastatin (80 mg) in unstable angina pectoris and non-Q-wave acute myocardial infarction. Am J Cardiol 2003, 92:298-301. This randomized study suggests that short-term high-dose atorvastatin (80 mg) suppresses the CRP increase usually seen during the first 5 days of an acute coronary syndrome.
46. Chan AW, Bhatt DL, Chew DP, et al.: Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation 2002, 105:691-696.
47. Furman MI, Gore JM, Anderson FA, et al.: Elevated leukocyte count and adverse hospital events in patients with acute coronary syndromes: findings from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2004, 147:42-48. This observational study of more than 8000 patients with acute coronary syndrome establishes that the initial leukocyte count is an independent predictor for in-hospital death and heart failure.
48. Simon DI, Xu H, Ortlepp S, et al.: 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997, 17:528-535.
49. Tam SH, Sassoli PM, Jordan RE, et al.: Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998, 98:1085-1091.
50. Lincoff AM, Kereiakes DJ, Mascelli MA, et al.: Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation 2001, 104:163-167.
51. Aggarwal A, Schneider DJ, Terrien EF, et al.: Comparison of effects of abciximab versus eptifibatide on C-reactive protein, interleukin-6, and interleukin-1 receptor antagonist after coronary arterial stenting. Am J Cardiol 2003, 91:1346-1349.
52. Merino A, Segura I, Vidal B, et al.: Eptifibatide blocks C-reactive protein increase after coronary angioplasty. J Am Coll Cardiol 2003, 41:233.
53. Ercan E, Tengiz I, Duman C, et al.: Effect of tirofiban on C-reactive protein in non-ST-elevation myocardial infarction. Am Heart J 2004, 147:E1. This study shows a sustained (at least 72-hour) attenuation of CRP elevation in patients with non-ST-elevation myocardial infarction treated by a 48-hour infusion of tirofiban.
54. Mahaffey KW, Granger CB, Nicolau JC, et al.: Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003, 108:1176-1183.
55. Granger CB, Mahaffey KW, Weaver WD, et al.: Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in myocardial infarction treated with angioplasty (COMMA) trial. Circulation 2003, 108:1184-1190. This randomized study shows that inhibition of the complement cascade by an anti-C5 complement antibody significantly reduces mortality and the incidence of cardiogenic shock when given as adjunctive therapy to primary PCI.
56. Hochman JS: Cardiogenic shock complicating acute myocardial infarction: expanding the paradigm. Circulation 2003, 107:2998-3002. This landmark paper summarizes major findings that support an involvement of the inflammatory system in the pathogenesis of cardiogenic shock and presents an expanded paradigm of cardiogenic shock that crucially involves inflammatory cytokines and NO.
57. de Werra I, Jaccard C, Corradin SB, et al.: Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia. Crit Care Med 1997, 25:607-613.
58. Geppert A, Steiner A, Zorn G, et al.: Multiple organ failure in patients with cardiogenic shock is associated with high plasma levels of interleukin-6. Crit Care Med 2002, 30:1987-1994.
59. Geppert A, Steiner A, Delle-Karth G, et al.: Usefulness of procalcitonin for diagnosing complicating sepsis in patients with cardiogenic shock. Intens Care Med 2003, 29:1384-1389.
60. Brunkhorst FM, Clark AL, Forycki ZF, et al.: Pyrexia, procalcitonin, immune activation and survival in cardiogenic shock: the potential importance of bacterial translocation. Int J Cardiol 1999, 72:3-10.
61. Cotter G, Moshkovitz Y, Kaluski E, et al.: The role of cardiac power and systemic vascular resistance in the pathophysiology and diagnosis of patients with acute congestive heart failure. Eur J Heart Fail 2003, 5:443-451.
62. Hochman JS, Sleeper LA, Webb JG, et al.: Early revascularization in acute myocardial infarction complicated by cardiogenic shock: SHOCK Investigators: should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999, 341:625-634.
63. Dzavik V, Sleeper LA, Cocke TP, et al.: Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003, 24:828-837. This study reveals that elderly patients (>75 years) selected for early revascularization have a lower mortality rate than those receiving a revascularization procedure later or never.
64. Webb JG, Lowe AM, Sanborn TA, et al.: Percutaneous coronary intervention for cardiogenic shock in the SHOCK trial. J Am Coll Cardiol 2003, 42:1380-1386 This substudy from the SHOCK trial showed that in patients with cardiogenic shock treated by PCI, successful revascularization is an important predictor of survival, whereas unsuccessful revascularization (TIMI-0 or -1 flow) is associated with a nearby 100% mortality rate within the next 7 days.
65. Zeymer U, Vogt A, Zahn R, et al.: Predictors of in-hospital mortality in 1333 patients with acute myocardial infarction complicated by cardiogenic shock treated with primary percutaneous coronary intervention (PCI): results of the primary PCI registry of the Arbeitsgemeinschaft Leitende Kardiologische Krankenhausarzte (ALKK). Eur Heart J 2004, 25:322-328. This large retrospective study demonstrates the importance of TIMI-3 flow for survival in patients with cardiogenic shock.
66. Tarantini G, Ramondo A, Napodano M, et al.: Myocardial perfusion grade and survival after percutaneous transluminal coronary angioplasty in patients with cardiogenic shock. Am J Cardiol 2004, 93:1081-1085. This study was the first to be published on myocardial perfusion and cardiogenic shock and shows that beyond TIMI-3 flow in the coronary arteries, myocardial reperfusion is an even more important predictor of survival in cardiogenic shock.
67. Chan AW, Chew DP, Bhatt DL, et al.: Long-term mortality benefit with the combination of stents and abciximab for cardiogenic shock complicating acute myocardial infarction. Am J Cardiol 2002, 89:132-130.
68. Antoniucci D, Valenti R, Migliorini A, et al.: Abciximab therapy improves survival in patients with acute myocardial infarction complicated by early cardiogenic shock undergoing coronary artery stent implantation. Am J Cardiol 2002, 90:353-357.
69. De Backer D, Creteur J, Dubois MJ, et al.: Microvascular alterations in patients with acute severe heart failure and cardiogenic shock. Am Heart J 2004, 147:91-99. This study showed that patients with cardiogenic shock have reduced perfusion of the small vessels and that these changes are more severe in nonsurvivors than in survivors.
70. Lopez A, Lorente JA, Steingrub J, et al.: Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Grit Care Med 2004, 32:21-30.
71. Cotter G, Kaluski E, Milo O, et al.: LINCS: L-NAME (a NO synthase inhibitor) in the treatment of refractory cardiogenic shock: a prospective randomized study. Eur Heart J 2003, 24:1287-1295. This paper reported that inhibition of NO synthase in patients with cardiogenic shock significantly decreases mortality by approximately 50%.